Cargando…

Comprehensive analysis of circular RNA profiling in AZD9291‐resistant non‐small cell lung cancer cell lines

BACKGROUND: Osimertinib (AZD9291), a third‐generation EGFR‐tyrosine kinase inhibitor, can effectively prolong survival in non‐small cell lung cancer (NSCLC) patients with EGFR mutations, particularly T790M mutations; however, acquired resistance to AZD9291 is inevitable, thus exploration of the targ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Tianxiang, Luo, Jizhuang, Gu, Yu, Huang, Jia, Luo, Qingquan, Yang, Yunhai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449233/ https://www.ncbi.nlm.nih.gov/pubmed/30883029 http://dx.doi.org/10.1111/1759-7714.13032

Ejemplares similares

AZD9291-resistant non-small cell lung cancer cell-derived exosomal lnc-MZT2A-5:1 induces the activation of fibroblasts
por: Song, Liwei, et al.
Publicado: (2021)

AZD9291-induced Acute Interstitial Lung Disease
por: Nie, Ke-Ke, et al.
Publicado: (2016)

Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line
por: Tang, Zheng-Hai, et al.
Publicado: (2016)

Osimertinib (AZD9291) increases radio-sensitivity in EGFR T790M non-small cell lung cancer
por: Wang, Nannan, et al.
Publicado: (2019)

Transformation to small-cell carcinoma as an acquired resistance mechanism to AZD9291: A case report
por: Li, Lin, et al.
Publicado: (2017)

A case report of toxic epidermal necrolysis associated with AZD-9291
por: Wang, Jie, et al.
Publicado: (2018)

AZD9291 Resistance Reversal Activity of a pH‐Sensitive Nanocarrier Dual‐Loaded with Chloroquine and FGFR1 Inhibitor in NSCLC
por: Gu, Yu, et al.
Publicado: (2020)

AZD9291 inactivates the PRC2 complex to mediate tumor growth inhibition
por: Zhang, Kai-li, et al.
Publicado: (2019)

Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M
por: Thress, Kenneth S., et al.
Publicado: (2015)

Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291)
por: Saad, Nibal, et al.
Publicado: (2017)

Exosomal long non-coding RNA MSTRG.292666.16 is associated with osimertinib (AZD9291) resistance in non-small cell lung cancer
por: Deng, Qinfang, et al.
Publicado: (2020)

Heterogeneity‐based, multiple mechanisms in the resistance to osimertinib (AZD9291): A case report
por: Liu, Yutao, et al.
Publicado: (2018)

Successful treatment after toxic epidermal necrolysis induced by AZD-9291 in a patient with non-small cell lung cancer: A case report
por: Li, Wen, et al.
Publicado: (2021)

Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model
por: Ku, Bo Mi, et al.
Publicado: (2018)

Author Correction: AZD9291 inactivates the PRC2 complex to mediate tumor growth inhibition
por: Zhang, Kai-li, et al.
Publicado: (2020)

High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells
por: Nanjo, Shigeki, et al.
Publicado: (2015)

Osimertinib (AZD9291), a Mutant-Selective EGFR Inhibitor, Reverses ABCB1-Mediated Drug Resistance in Cancer Cells
por: Zhang, Xiao-Yu, et al.
Publicado: (2016)

The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma
por: Liu, Xuejiao, et al.
Publicado: (2019)

Non‐small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report
por: Huang, Jing, et al.
Publicado: (2018)

DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild‐type NSCLC cells to AZD9291
por: Li, Yang‐ling, et al.
Publicado: (2019)

Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: a case report
por: Wang, Junhui, et al.
Publicado: (2019)

SHR‐A1403, a novel c‐mesenchymal‐epithelial transition factor (c‐Met) antibody‐drug conjugate, overcomes AZD9291 resistance in non‐small cell lung cancer cells overexpressing c‐Met
por: Tong, Mengya, et al.
Publicado: (2019)

Advanced lung adenocarcinoma (LUAD) patient with EGFR mutations benefited from multiline combination targeted therapies after osimertinib (AZD9291) resistance: a case report
por: Chen, Jingyu, et al.
Publicado: (2022)

Comprehensive analysis of prognostic predictors for patients with limited-stage small-cell lung cancer who underwent resection followed by adjuvant chemotherapy
por: Feng, Jian, et al.
Publicado: (2021)

Solid predominant histologic subtype and early recurrence predict poor postrecurrence survival in patients with stage I lung adenocarcinoma
por: Luo, Jizhuang, et al.
Publicado: (2016)

Visceral pleural invasion predict a poor survival among lung adenocarcinoma patients with tumor size ≤ 3cm
por: Chen, Tianxiang, et al.
Publicado: (2017)

Consecutive severe immune-related adverse events after PD-1 inhibitor induction and surgery in locally advanced non-small cell lung cancer: a case report
por: Zhao, Hang, et al.
Publicado: (2021)

The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer
por: Jiang, Long, et al.
Publicado: (2021)

Comprehensive Characterization of Circular RNAs in Neuroblastoma Cell Lines
por: Zhang, Li, et al.
Publicado: (2020)

Comprehensive genomic profiling of combined small cell lung cancer
por: Zhang, Jing, et al.
Publicado: (2021)

Evaluation of dynamic image progression of minimally invasive and preinvasive lung adenocarcinomas
por: Chen, Tianxiang, et al.
Publicado: (2021)

A randomized placebo-controlled clinical study of nab-paclitaxel as second-line chemotherapy for patients with advanced non-small cell lung cancer in China
por: Wu, Yueming, et al.
Publicado: (2017)

Attempt of peripheral nerve reconstruction during lung cancer surgery
por: Li, Hanyue, et al.
Publicado: (2018)

Comprehensive circular RNA profiling reveals that circular RNA100783 is involved in chronic CD28-associated CD8(+)T cell ageing
por: Wang, Yu-hong, et al.
Publicado: (2015)

A uniportal right upper lobectomy by three-arm robotic-assisted thoracoscopic surgery using the da Vinci (Xi) Surgical System in the treatment of early-stage lung cancer
por: Yang, Yunhai, et al.
Publicado: (2021)

Comprehensive characterization of circular RNAs in ~ 1000 human cancer cell lines
por: Ruan, Hang, et al.
Publicado: (2019)

Emerging roles of circular RNAs in non-small cell lung cancer
por: Li, Shanshan, et al.
Publicado: (2021)

Osimertinib as induction therapy for oligometastatic non-small cell lung cancer with EGFR mutation: a case report
por: Wu, Han, et al.
Publicado: (2022)

Comprehensive Proteomic Profiling of Aldehyde Dehydrogenases in Lung Adenocarcinoma Cell Lines
por: Zhang, Qing, et al.
Publicado: (2011)

Screening Circular RNAs Related to Acquired Gefitinib Resistance in Non-small Cell Lung Cancer Cell Lines
por: Wen, Chunjie, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4mccbnpf78vlira2iolv5rf9hs